Literature DB >> 1845996

Enhancement of expression of exogenous genes by 2-aminopurine. Regulation at the post-transcriptional level.

D V Kalvakolanu1, S K Bandyopadhyay, R K Tiwari, G C Sen.   

Abstract

In human and mouse cell lines, expression of exogenous genes was enhanced by treatment with 2-aminopurine (2-AP). Chloramphenicol acetyltransferase (CAT) and neomycin phosphotransferase activities were increased by up to 50-fold upon 2-AP treatment of cells permanently transfected with genes encoding these enzymes. Neomycin phosphotransferase activity was also increased by this treatment in cells infected with a retroviral vector carrying the neomycin phosphotransferase gene. 2-AP-mediated increase in CAT activity was observed in various cell lines which had been permanently transfected with chimeric CAT genes containing transcriptional regulatory elements of the interferon-inducible genes 6-16 and 561, SV40 early genes, mouse mammary tumor viral gene, or metallothionein II gene. The increase in the cellular CAT enzymatic activity was due to an elevated level of CAT protein. The 2-AP-mediated enhancement of CAT expression was operative at the translational level; the rate of transcription of CAT mRNA or its steady-state level was affected only marginally. The translational up-regulation by 2-AP was restricted to the genes introduced from outside; there was no gross change in the rate of synthesis of other cellular proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1845996

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Distinct structural features of caprin-1 mediate its interaction with G3BP-1 and its induction of phosphorylation of eukaryotic translation initiation factor 2alpha, entry to cytoplasmic stress granules, and selective interaction with a subset of mRNAs.

Authors:  Samuel Solomon; Yaoxian Xu; Bin Wang; Muriel D David; Peter Schubert; Derek Kennedy; John W Schrader
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

2.  Engineering of recombinant soluble CD46: an inhibitor of complement activation.

Authors:  D Christiansen; J Milland; B R Thorley; I F McKenzie; P L Mottram; L J Purcell; B E Loveland
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

3.  Identification of positive and negative transcriptional regulatory elements of the rabbit angiotensin-converting enzyme gene.

Authors:  T Y Goraya; S P Kessler; R S Kumar; J Douglas; G C Sen
Journal:  Nucleic Acids Res       Date:  1994-04-11       Impact factor: 16.971

4.  Two distinct pathways of interferon induction as revealed by 2-aminopurine.

Authors:  L Daigneault; A Haggarty; Q H Meng; D Skup
Journal:  Nucleic Acids Res       Date:  1992-06-11       Impact factor: 16.971

5.  2-Aminopurine selectively inhibits splicing of tumor necrosis factor alpha mRNA.

Authors:  N Jarrous; F Osman; R Kaempfer
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

6.  Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: block in transcriptional complex formation.

Authors:  D V Kalvakolanu; S K Bandyopadhyay; M L Harter; G C Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  Inducible transcriptional activation of the human immunodeficiency virus long terminal repeat by protein kinase inhibitors.

Authors:  F L Brown; E Tahaoglu; G J Graham; J J Maio
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

8.  Deep sequencing reveals complex spurious transcription from transiently transfected plasmids.

Authors:  Jana Nejepinska; Radek Malik; Martin Moravec; Petr Svoboda
Journal:  PLoS One       Date:  2012-08-16       Impact factor: 3.240

9.  2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.

Authors:  David Sharon; Michael Schümann; Sheena MacLeod; Robyn McPherson; Shyambabu Chaurasiya; Andrew Shaw; Mary M Hitt
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.